| Form type | Sec Links | Description | Filing date | Reporting date |
|---|---|---|---|---|
| 8-K | Report | Data | 8-K | Jun 20, 2024 | Jun 18, 2024 |
| 10-Q | Report | Data | 10-Q | May 7, 2024 | Mar 31, 2024 |
| 8-K | Report | Data | 8-K | May 7, 2024 | May 7, 2024 |
| 8-K | Report | Data | 8-K | Apr 8, 2024 | Apr 8, 2024 |
| 10-K | Report | Data | 10-K | Mar 12, 2024 | Dec 31, 2023 |
| 8-K | Report | Data | 8-K | Mar 12, 2024 | Mar 12, 2024 |
| SC 13D/A | Report | SC 13D/A | Feb 20, 2024 | |
| SC 13G/A | Report | SC 13G/A | Feb 14, 2024 | |
| SC 13G/A | Report | NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13G/A(#2E) | Feb 14, 2024 | |
| SC 13G/A | Report | SC 13G/A | Feb 14, 2024 | |
| SC 13G/A | Report | Feb 14, 2024 | ||
| SC 13G | Report | Feb 14, 2024 | ||
| SC 13G | Report | SC 13G | Feb 14, 2024 | |
| SC 13G/A | Report | Feb 14, 2024 | ||
| SC 13D/A | Report | SC 13D/A | Feb 12, 2024 | |
| SC 13G/A | Report | INOZYME PHARMA, INC. | Feb 7, 2024 | |
| SC 13G/A | Report | SC 13G/A | Feb 5, 2024 | |
| SC 13G/A | Report | Jan 16, 2024 | ||
| 10-Q | Report | Data | 10-Q | Nov 7, 2023 | Sep 30, 2023 |
| 8-K | Report | Data | 8-K | Nov 7, 2023 | Nov 7, 2023 |
| 8-K | Report | Data | 8-K | Sep 26, 2023 | Sep 26, 2023 |
| SC 13D/A | Report | SC 13D/A | Aug 11, 2023 | |
| 10-Q | Report | Data | 10-Q | Aug 8, 2023 | Jun 30, 2023 |
| 8-K | Report | Data | 8-K | Aug 8, 2023 | Aug 8, 2023 |
| SC 13D/A | Report | SC 13D/A | Aug 8, 2023 | |
| 8-K | Report | Data | 8-K | Jul 28, 2023 | Jul 27, 2023 |
| 8-K | Report | Data | 8-K | Jul 26, 2023 | Jul 26, 2023 |
| 8-K | Report | Data | 8-K | Jun 27, 2023 | Jun 27, 2023 |
| 8-K | Report | Data | 8-K | Jun 14, 2023 | Jun 13, 2023 |
| SC 13G | Report | May 31, 2023 | ||
| SC 13D/A | Report | SC 13D/A | May 23, 2023 | |
| 10-Q | Report | Data | 10-Q | May 9, 2023 | Mar 31, 2023 |
| 8-K | Report | Data | 8-K | May 9, 2023 | May 9, 2023 |
| SC 13D/A | Report | SC 13D/A | Apr 4, 2023 | |
| 10-K | Report | Data | 10-K | Mar 22, 2023 | Dec 31, 2022 |
| 8-K | Report | Data | 8-K | Mar 22, 2023 | Mar 22, 2023 |
| 8-K | Report | Data | 8-K | Mar 10, 2023 | Mar 10, 2023 |
| SC 13G | Report | SC 13G | Mar 7, 2023 | |
| 8-K | Report | Data | 8-K | Feb 16, 2023 | Feb 15, 2023 |
| SC 13G/A | Report | SC 13G/A | Feb 14, 2023 | |
| SC 13G | Report | SC 13G | Feb 14, 2023 | |
| SC 13G/A | Report | Feb 14, 2023 | ||
| SC 13G/A | Report | Feb 14, 2023 | ||
| SC 13G | Report | CHI ADVISORS LLC | Feb 13, 2023 | |
| SC 13G/A | Report | Feb 10, 2023 | ||
| SC 13G/A | Report | INOZYME PHARMA, INC. | Feb 9, 2023 | |
| 8-K | Report | Data | 8-K | Dec 8, 2022 | Dec 7, 2022 |
| 8-K | Report | Data | 8-K | Dec 8, 2022 | Dec 8, 2022 |
| 10-Q | Report | Data | 10-Q | Nov 10, 2022 | Sep 30, 2022 |
| 8-K | Report | Data | 8-K | Nov 10, 2022 | Nov 10, 2022 |
| 10-Q | Report | Data | 10-Q | Aug 15, 2022 | Jun 30, 2022 |
| 8-K | Report | Data | 8-K | Aug 15, 2022 | Aug 15, 2022 |
| 8-K | Report | Data | 8-K | Jul 26, 2022 | Jul 25, 2022 |
| 8-K | Report | Data | 8-K | Jul 19, 2022 | Jul 19, 2022 |
| 8-K | Report | Data | 8-K | Jun 10, 2022 | Jun 10, 2022 |
| 10-Q | Report | Data | 10-Q | May 10, 2022 | Mar 31, 2022 |
| 8-K | Report | Data | 8-K | May 10, 2022 | May 10, 2022 |
| SC 13G | Report | SC 13G | Apr 29, 2022 | |
| SC 13D | Report | SC 13D | Apr 28, 2022 | |
| SC 13D/A | Report | SC 13D/A | Apr 28, 2022 | |
| SC 13G | Report | Apr 25, 2022 | ||
| 8-K | Report | Data | 8-K | Apr 19, 2022 | Apr 14, 2022 |
| SC 13G | Report | Apr 18, 2022 | ||
| 8-K | Report | Data | 8-K | Apr 12, 2022 | Apr 12, 2022 |
| 8-K | Report | Data | 8-K | Apr 4, 2022 | Apr 4, 2022 |
| 10-K/A | Report | Data | 10-K/A | Mar 31, 2022 | Dec 31, 2021 |
| 8-K | Report | Data | 8-K | Mar 15, 2022 | Mar 15, 2022 |
| 10-K | Report | Data | 10-K | Mar 15, 2022 | Dec 31, 2021 |
| 8-K | Report | Data | 8-K | Mar 8, 2022 | Mar 2, 2022 |
| SC 13G/A | Report | SC 13G/A | Feb 14, 2022 | |
| SC 13G/A | Report | Feb 11, 2022 | ||
| SC 13G/A | Report | INOZYME PHARMA, INC. | Feb 10, 2022 | |
| SC 13G/A | Report | NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13GA(#1) | Feb 7, 2022 | |
| SC 13G/A | Report | SCHEDULE 13G/A | Nov 15, 2021 | |
| 8-K | Report | Data | 8-K | Nov 15, 2021 | Nov 15, 2021 |
| 10-Q | Report | Data | 10-Q | Nov 9, 2021 | Sep 30, 2021 |
| 8-K | Report | Data | 8-K | Nov 9, 2021 | Nov 9, 2021 |
| 10-Q | Report | Data | INZY_10-Q_6312021 | Aug 11, 2021 | Jun 30, 2021 |
| 8-K | Report | 8-K | Aug 11, 2021 | Aug 11, 2021 |
| SC 13D/A | Report | SC 13D/A | Jul 30, 2021 | |
| 8-K | Report | 8-K | Jun 24, 2021 | Jun 23, 2021 |
| 10-Q | Report | Data | 10-Q | May 12, 2021 | Mar 31, 2021 |
| 8-K | Report | 8-K | May 12, 2021 | May 12, 2021 |
| SC 13G | Report | INOZYME PHARMA, INC. | May 10, 2021 | |
| 8-K | Report | 8-K | May 7, 2021 | May 6, 2021 |
| 8-K | Report | 8-K | Apr 21, 2021 | Apr 19, 2021 |
| SC 13D/A | Report | SC 13D/A | Mar 30, 2021 | |
| 10-K | Report | Data | 10-K | Mar 25, 2021 | Dec 31, 2020 |
| 8-K | Report | 8-K | Mar 25, 2021 | Mar 25, 2021 |
| SC 13D | Report | SCHEDULE 13D | Mar 4, 2021 | |
| SC 13G | Report | SCHEDULE 13G | Feb 16, 2021 | |
| SC 13G | Report | NEW ENTERPRISE ASSOCIATES 15, L.P. / INOZYME PHARMA -- 13G | Feb 12, 2021 | |
| SC 13G | Report | SC 13G | Feb 9, 2021 | |
| SC 13D/A | Report | SC 13D - AMENDMENT NO. 2 | Feb 1, 2021 | |
| 10-Q | Report | Data | 10-Q | Nov 12, 2020 | Sep 30, 2020 |
| 8-K | Report | 8-K | Nov 12, 2020 | Nov 12, 2020 |
| SC 13D/A | Report | SC 13D/A | Oct 5, 2020 | |
| 10-Q | Report | Data | 10-Q | Sep 3, 2020 | Jun 30, 2020 |
| 8-K | Report | 8-K | Sep 3, 2020 | Sep 3, 2020 |
| SC 13D | Report | SC 13D | Aug 7, 2020 | |
| SC 13G | Report | Aug 6, 2020 | ||
| SC 13D | Report | SC 13D | Aug 4, 2020 | |
| SC 13D | Report | SC 13D | Jul 29, 2020 | |
| 8-K | Report | 8-K | Jul 28, 2020 | Jul 28, 2020 |